Sponsor Directory

Genentech, Inc. clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1397

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Bronchiolitis Obliterans, Graft Vs Host Disease
Interventions: Pirfenidone 267 MG [Esbriet]; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant, Chemotherapy with Eribulin; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HER-2 Positive Metastatic Breast Cancer
Interventions: Etoposide, Trastuzumab; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HER2 Positive Breast Cancer, Left Ventricular Function Systolic Dysfunction
Interventions: Trastuzumab, Pertuzumab, Ado Trastuzumab Emtansine; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Lung Cancer
Interventions: Pemetrexed, Gemcitabine, Bevacizumab, Carboplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 70 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 18
States / cities: Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 14 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Valganciclovir, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Kidney Disease
Interventions: Pirfenidone, matching placebo; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: San Diego, California • San Francisco, California

Conditions: Lymphoma
Interventions: Fludarabine, Mitoxantrone, Rituximab, Zevalin, Dexamethasone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 1,613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 522
States / cities: Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more

Conditions: Malignant Glioma, Glioblastoma, Gliosarcoma
Interventions: Bevacizumab, Temozolomide, Radiation Therapy (XRT), Topotecan; Drug · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neoplasms
Interventions: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a humanized agonist anti-OX40 monoclonal antibody; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 5 more

Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
Interventions: Rituximab, Azathioprine; Biological · Drug
Lead sponsor: Cambridge University Hospitals NHS Foundation Trust; Other
Eligibility: 15 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota + 6 more

About this Genentech, Inc. sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Genentech, Inc. clinical trials

Filter and sort this sponsor

Live official records

The Safety and Tolerability of Pirfenidone for BOS After HCT

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

Cardiac Safety Study in Patients With HER2 + Breast Cancer

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)

Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease

Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Rituximab Vasculitis Maintenance Study

About this Genentech, Inc. sponsor directory page